Satellos Bioscience Inc. (MSLE) Income Statement
MSLE 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMSLE revenue and net income
MSLE growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MSLE quarterly EPS vs estimates
Satellos Bioscience beat the analyst EPS estimate in 2 of the last 5 quarters. Next report: November 13, 2026 (estimate $-0.44).
MSLE income statement
| 2025 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $5,087 | $3.7M | $892,781 | $3,146 | $1,533 | $23,831 | $27,619 | $21,955 |
| Gross profit | −$5,087 | −$3.7M | −$892,781 | −$3,146 | −$1,533 | −$23,831 | −$27,619 | −$21,955 |
| Research & development | $18.4M | $3.7M | $892,781 | $942,488 | $1.4M | $798,517 | $568,798 | $625,694 |
| Sales, general & admin | $7.4M | $4.7M | $987,528 | — | — | — | — | — |
| Total operating expenses | $26.5M | $4.7M | $1.9M | $2.3M | $2.2M | $1.5M | $1.2M | $2.2M |
| Operating income | −$26.5M | −$8.4M | −$2.8M | −$2.3M | −$2.2M | −$1.5M | −$1.2M | −$2.2M |
| Interest income | $1.4M | $46,419 | — | — | — | — | — | — |
| Interest expense | — | $0 | $499 | — | — | — | — | — |
| Income before taxes | −$24.7M | −$11.3M | −$1.6M | −$2.3M | −$1.7M | −$1.3M | −$1.5M | −$1.8M |
| Income taxes | $172,000 | $5,000 | −$271,186 | −$272,011 | — | — | — | — |
| Net income | −$24.9M | −$11.3M | −$1.6M | −$2.0M | −$1.7M | −$1.3M | −$1.5M | −$1.8M |
| EBITDA | −$26.5M | −$8.1M | −$1.6M | −$2.3M | −$2.2M | −$1.5M | −$1.2M | −$2.2M |
| EPS (diluted) | −$1.76 | −$2.77 | −$1.73 | −$2.83 | −$3.74 | −$2.70 | −$3.15 | −$3.85 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $975 | $986 | $1,015 | $1,977 | $1,017 | $997 | $2,217 | $2,997 | $2,701 | $2,000 | $1,994 | $1.6M |
| Gross profit | −$974 | −$986 | −$1,015 | −$1,977 | −$1,017 | −$996 | −$2,217 | −$2,997 | −$2,701 | −$2,000 | −$1,994 | −$1.6M |
| Research & development | $9.4M | $7.3M | $5.5M | $4.0M | $4.4M | $4.5M | $3.2M | $4.9M | $6.0M | $3.6M | $2.7M | $1.6M |
| Sales, general & admin | $2.5M | $2.3M | $2.0M | $1.9M | $1.7M | $1.8M | $1.7M | — | — | — | — | $1.5M |
| Total operating expenses | $11.9M | $10.0M | $7.6M | $6.0M | $6.4M | $6.5M | $5.0M | $6.7M | $8.3M | $6.2M | $4.5M | $1.5M |
| Operating income | −$11.9M | −$10.0M | −$7.6M | −$6.0M | −$6.4M | −$6.5M | −$5.0M | −$6.7M | −$8.3M | −$6.2M | −$4.5M | −$3.1M |
| Interest income | $571,000 | $421,000 | $256,000 | $349,000 | $362,000 | $393,000 | $230,000 | — | — | — | — | — |
| Interest expense | — | — | — | — | — | — | $0 | — | — | — | $55,822 | $112,196 |
| Income before taxes | −$11.4M | −$9.7M | −$7.2M | −$5.8M | −$5.6M | −$6.1M | −$9.0M | −$6.0M | −$6.9M | −$6.5M | −$3.6M | −$4.1M |
| Income taxes | $42,882 | $33,000 | $58,000 | $19,000 | $32,000 | $63,000 | — | — | — | — | — | — |
| Net income | −$11.4M | −$9.8M | −$7.3M | −$5.8M | −$5.6M | −$6.1M | −$9.0M | −$6.0M | −$6.9M | −$6.5M | −$3.6M | −$4.1M |
| EBITDA | −$11.9M | −$10.0M | −$7.6M | −$6.0M | −$6.4M | −$6.5M | −$5.0M | −$6.7M | −$8.3M | −$6.2M | −$4.5M | −$3.1M |
| EPS (diluted) | −$0.56 | −$0.53 | −$0.50 | −$0.42 | −$0.39 | −$0.44 | −$0.69 | −$0.44 | −$0.55 | −$0.53 | −$0.26 | −$0.44 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MSLE's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MSLE financial results
Satellos Bioscience reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $24.9 million. Diluted earnings per share came to −$1.76.
See the MSLE stock overview for the latest quote and news, or the MSLE chart for price history and technical indicators.
MSLE income statement FAQ
Does Satellos Bioscience have revenue?
Satellos Bioscience reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Satellos Bioscience profitable?
No. Satellos Bioscience reported a net loss of $24.9 million in fiscal 2025.
How much does Satellos Bioscience spend on research and development?
Satellos Bioscience spent $18.4 million on research and development in fiscal 2025.
What are Satellos Bioscience's earnings per share?
Satellos Bioscience earned $-1.76 per diluted share in fiscal 2025, compared with $-2.77 a year earlier.
When will Satellos Bioscience report its next earnings?
Satellos Bioscience is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Satellos Bioscience's fiscal year end?
Satellos Bioscience's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.